Moreover, a recent study suggested that low TMEM170B expression is an independent predictor of poor overall survival (OS) in patients with breast carcinoma (BRCA) (p < 0.01) and that TMEM170B could act as a tumor suppressor to antagonize the protumorigenic Wnt/β-catenin signaling pathway Li et al. (2018). This evidence concerns the gene TMEM170B and breast carcinoma.